Home

Avidity Biosciences, Inc. - Common Stock (RNA)

32.93
+0.30 (0.92%)

Avidity Biosciences Inc is a biotechnology company focused on developing innovative therapies that leverage its proprietary AOC platform, which stands for antibody-oligonucleotide conjugates

This platform aims to deliver therapeutic oligonucleotides directly to specific cells using antibodies, thereby enhancing the precision and effectiveness of treatments for various diseases, including genetic disorders and cancer. The company's research is centered around improving the delivery and efficacy of RNA-based therapies, with the goal of transforming the treatment landscape for patients through targeted and personalized medicine.

SummaryNewsPress ReleasesChartHistoricalFAQ
This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
Avidity Biosciences' stock has performed incredibly well in 2024. Its Duchenne muscular dystrophy drug is showing strong results in trials.
Via MarketBeat · August 19, 2024
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023
FN Media Group Presents USA News Group News Commentary   Vancouver, BC – September 13, 2023 – USA News Group  –  Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food and Drug Administration (FDA) granted several approvals and new Fast Track designations towards the end of 2022 […]
Via FinancialNewsMedia · September 13, 2023
Avidity Biosciences (NASDAQ: RNA) Posts Positive Phase 1/2 MARINA Data on AOC 1001, Announcing the First Successful Delivery of RNA to Muscle
Avidity Biosciences, Inc. (NASDAQRNA) is engaged as a biopharmaceutical company, which is focused on developing a new class of
Via Spotlight Growth · December 14, 2022